Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
16 hedge funds and large institutions have $2.42M invested in Hepion Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 2 closing their positions.
50% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 2
7% more funds holding
Funds holding: 15 → 16 (+1)
39% less capital invested
Capital invested by funds: $4M → $2.42M (-$1.58M)
75% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$77.2K |
| 2 |
VF
Virtu Financial
New York
|
+$47.3K |
| 3 |
JP Morgan Chase
New York
|
+$4.16K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$378 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
-$337K |
| 2 |
Morgan Stanley
New York
|
-$44.1K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$19.5K |
| 4 |
Osaic Holdings
Scottsdale,
Arizona
|
-$16.7K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.27K |
HEPA Hedge Fund Activity: Q4 2023 in Review
16 of the 6,869 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q4 2023, worth a combined $2.42M — down 39% from $4M a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new HEPA positions and 2 closed out — a net gain of 1 holder — while 1 added to existing stakes and 4 trimmed.
The largest buyer was Armistice Capital, adding an estimated $77.2K. The largest seller was Octagon Capital Advisors, exiting entirely with an estimated $337K sold.
- 16 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q4 2023, up from 15 in Q3 2023.
- Funds reported $2.42M of Hepion Pharmaceuticals stock for Q4 2023, down 39% quarter-over-quarter.
- 3 funds opened new Hepion Pharmaceuticals positions in Q4 2023 and 2 closed out, a net change of +1 holder.
- The largest Hepion Pharmaceuticals buyer in Q4 2023 was Armistice Capital, an estimated $77.2K added.
- The largest Hepion Pharmaceuticals seller in Q4 2023 was Octagon Capital Advisors, an estimated $337K sold.
Based on aggregated 13F filings for Q4 2023.